Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study

Jorge E Cortes; Jeff H Lipton; Vamsi Kota; Fausto Castagnetti; Sarit Assouline; Tim H Brümmendorf; Eric Leip; Andrea Viqueira; Carlo Gambacorti-Passerini

doi:10.3324/haematol.2022.281944

Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study

Haematologica. 2023 Dec 1;108(12):3454-3459. doi: 10.3324/haematol.2022.281944.

Authors

Jorge E Cortes¹, Jeff H Lipton², Vamsi Kota³, Fausto Castagnetti⁴, Sarit Assouline⁵, Tim H Brümmendorf⁶, Eric Leip⁷, Andrea Viqueira⁸, Carlo Gambacorti-Passerini⁹

Affiliations

¹ Georgia Cancer Center, Augusta, GA. [email protected].
² Princess Margaret Cancer Centre, Toronto, ON.
³ Georgia Cancer Center, Augusta, GA.
⁴ Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna.
⁵ McGill University, Montreal, QC.
⁶ Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD).
⁷ Pfizer Inc, Cambridge, MA.
⁸ Pfizer SLU, Madrid.
⁹ University of Milano-Bicocca, Monza.

No abstract available

Publication types

Clinical Trial, Phase II
Clinical Trial, Phase I
Letter

MeSH terms

Antineoplastic Agents* / adverse effects
Humans
Imatinib Mesylate / therapeutic use
Leukemia* / drug therapy
Nitriles / therapeutic use
Philadelphia Chromosome
Protein Kinase Inhibitors / adverse effects
Tyrosine Kinase Inhibitors

Substances

bosutinib
Tyrosine Kinase Inhibitors
Imatinib Mesylate
Nitriles
Protein Kinase Inhibitors
Antineoplastic Agents

Grants and funding

Funding: This study (clinicaltrials gov. identifier: NCT00261846) was sponsored by Pfizer. Medical writing support was provided by Katy Beck, PhD, of Engage Scientific Solutions (Horsham, UK) and funded by Pfizer.